A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 434
- 试验地点
- 83
- 主要终点
- Change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) total score at Endpoint
研究概览
简要总结
A clinical study that will meaure how well SEP-363856 works and how safe it is in adults with Generalized Anixety Disorder. This study will be accepting both male and female subjects between the ages of 18 years and 65 years old. The study will be held in Approximately 50 global study centers and approximately 15 additional centers for a separate Japan population. Participation in the study can be up to approximately 12 weeks.
详细描述
This is a multicenter, randomized, double-blind, parallel-group, flexible dose, outpatient study evaluating the efficacy and safety of SEP-363856 flexibly dosed (50 - 75 mg/day) versus placebo over an 8-week Treatment Period in subjects with GAD. This study is projected to randomize approximately 434 subjects to 2 treatment groups (SEP-363856 [50 - 75 mg/day] or placebo) in a 1:1 ratio.
Approximately 30 additional subjects (N = 15 per treatment group) are projected to enroll in the Japan Cohort. Treatment assignment will be stratified by country. Study drug will be taken at approximately the same time each evening at bedtime .
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
double blind
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •(list is not all inclusive)
- •Male or female subject between 18 to 65 years of age.
- •Subject meets DSM-5 criteria for a diagnosis of Generalized Anxiety Disorder.
- •Subject must be willing and able to comply with the study procedures and visit schedule and must be able to understand and follow verbal and written instructions.
排除标准
- •(list is not all inclusive)
- •Subject has DSM-5-based diagnosis of any disorder other than Generalized Anxiety Disorder that was the primary focus of treatment within 12 months before Screening.
- •Subjects who report an inadequate response to more than 3 antidepressant treatments
- •Subject is at significant risk of harming self or others based on Investigator's judgment.
- •Subject has any clinically significant unstable medical condition or any clinically significant chronic disease that in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in the study.
- •Female subject who is pregnant, lactating, or plans to get pregnant during the study.
研究组 & 干预措施
SEP-363856
dosed once daily tablet
干预措施: SEP-363856 (Drug)
Placebo
dosed once daily tablet
干预措施: Placebo (Drug)
结局指标
主要结局
Change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) total score at Endpoint
时间窗: Week 8
The HAM-A scale consists of 14 items, each defined by a series of symptoms. Each item is rated on a 5-point (0-4) scale, with higher scores indicating greater severity.
次要结局
- Change from Baseline in Clinical Global Impression-Severity (CGI-S) score at Endpoint(Week 8)